United States VOQUEZNA TRIPLE and DUAL PAKs Drug Insights and Market Forecasts, 2019-2022 and 2023-2032 - ResearchAndMarkets.com
20 Dec 2023
Drug ApprovalNDAClinical Result
DUBLIN--(BUSINESS WIRE)--The "US VOQUEZNA TRIPLE and DUAL PAKs Drug Insight and Market Forecast - 2032" drug pipelines has been added to ResearchAndMarkets.com's offering.
'US VOQUEZNA TRIPLE and DUAL PAKs Drug Insight and Market Forecast - 2032'
This report provides comprehensive insights about VOQUEZNA TRIPLE and DUAL PAKs for Helicobacter pylori (H. pylori) infection in the United States. A detailed picture of the VOQUEZNA TRIPLE and DUAL PAKs for H. pylori in the United States for the study period 2019 -2032 is provided in this report along with a detailed description of the VOQUEZNA TRIPLE and DUAL PAKs for H. pylori.
The report provides insights about mechanism of action, dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the VOQUEZNA TRIPLE and DUAL PAKs market forecast analysis for H. pylori in the US, SWOT, analysts' views, comprehensive overview of market competitors, and brief about other emerging therapies in H. pylori.
Drug Summary
VOQUEZNA TRIPLE and DUAL PAKs developed by Phathom Pharmaceuticals are co-packaged products containing potassium-competitive acid blockers (P-CABs) in combination with antibiotics for the treatment of H. pylori infection in adults.
VOQUEZNA TRIPLE PAK contains vonoprazan, a PCAB, with amoxicillin, a penicillin class antibacterial with a broad spectrum of bactericidal activity against many gram-positive and gram-negative microorganisms, and clarithromycin, a semi-synthetic macrolide antimicrobial for oral use, while, the DUAL PAK contains vonoprazan and amoxicillin only.
Vonoprazan is the first novel acid suppressant from a new drug class to be approved in the US in over 30 years. However, it is approved for the treatment of H. pylori infection and other acid-related diseases in many countries, including Japan.
Vonoprazan rapidly increases intragastric pH and maintains it to a greater degree than PPIs, leading to higher H. pylori eradication rates. Compared to PPI lansoprazole triple therapy, vonoprazan containing VOQUEZNA treatment regimens demonstrated superior eradication rates in various clinical trials for treating H. pylori infection in adults.
Phathom pharmaceutical is also developing vonoprazan-based regimes for the treatment of erosive esophagitis (EE), for which it has submitted an NDA to the FDA, and non-erosive reflux disease (NERD).
VOQUEZNA TRIPLE and DUAL PAKs Analytical Perspective
In-depth VOQUEZNA TRIPLE and DUAL PAKs Market Assessment
This report provides a detailed market assessment of VOQUEZNA TRIPLE and DUAL PAKs for H. pylori in the United States. This segment of the report provides forecasted sales data from 2023 to 2032.
VOQUEZNA TRIPLE and DUAL PAKs Clinical Assessment
The report provides the clinical trials information of VOQUEZNA TRIPLE and DUAL PAKs for H. pylori covering trial interventions, trial conditions, trial status, start and completion dates.
Report Highlights
In the coming years, the market scenario for H. pylori is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence VOQUEZNA TRIPLE and DUAL PAKs dominance.
Other emerging products for H. pylori are expected to give tough market competition to VOQUEZNA TRIPLE and DUAL PAKs and launch of late-stage emerging therapies in the near future will significantly impact the market.
A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of VOQUEZNA TRIPLE and DUAL PAKs in H. pylori.
The in-depth analysis of the forecasted sales data of VOQUEZNA TRIPLE and DUAL PAKs from 2023 to 2032 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the VOQUEZNA TRIPLE and DUAL PAKs in H. pylori.
Key Topics Covered:
1. Report Introduction
2. VOQUEZNA TRIPLE and DUAL PAKs Overview in H. pylori
2.1. Product Detail
2.2. Clinical Development
2.2.1. Clinical studies
2.2.2. Clinical trials information
2.2.3. Safety and efficacy
2.3. Regulatory Milestone
2.4. Other Developmental Activities
2.5. Product Profile
3. Competitive Landscape (Marketed Therapies)
4. Competitive Landscape (Late-stage Emerging Therapies)
5. VOQUEZNA TRIPLE and DUAL PAKs Market Assessment
5.1. Market Outlook of VOQUEZNA TRIPLE and DUAL PAKs in H. pylori
5.2. The United States Analysis
5.2.1. Market Size of VOQUEZNA TRIPLE and DUAL PAKs in the United States for H. pylori
6. SWOT Analysis
7. Analysts' Views
For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/imqb0t
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Targets
-Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.